Clinical Trial Update: Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial update discusses evaluating the optimal duration of therapy with oral angiogenesis inhibitors in patients with renal cell carcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Renal Cell Carcinoma

Snippet

Sponsor: Radboud University Medical Center | Conditions: Renal Cell Carcinoma, Gastrointestinal Stromal Tumor | Phase 4 | Status: UNKNOWN